The company’s turnover is expected to touch Rs 340 crore by the end of March 2016
Kolkata’s leading pharmaceutical company Albert David, a unit of the Kothari group, has undertaken a range of robust initiatives to maximise its growth. The company aims to develop brands and generate maximise revenue from them in the current fiscal year.
“In the current fiscal, we plan to further strengthen evict range by launching EVICT-XF,” said Kamal Prasad Mundhra, Executive Director, Albert David.
Albert David, which makes pharma formulations, bulk drugs and injections, has three manufacturing plants — in Kolkata (for tablets and powder, small volume parenterals, oral liquids, bulk drugs), Ghaziabad (for IV fluids in glass and polythene containers using the latest Form-Fill-Seal (FFS) technology and small volume parenterals) and Mandideep (disposable syringes and needles).
In the last fiscal (2014-15), the company, touched a turnover of Rs 320 crore and is expecting to touch Rs 340 crore by the end of March 2016.
The company has successfully launched Alamin Liquid and Alamin RLD (L-Arginine Sachet) in the last fiscal year.
Mundhra said, “The success of Derek & Breaze range has opened up the possibilities to venture in pre-probiotic and respiratory markets. Also we shall further strengthen our Gynae portfolio.”
Mundhra further added, “The company has given much thrust on its research and development initiatives. The company has made significant investments in fully renovating and expanding its R&D facility at Kolkata. The facility had been further equipped with more analytical and functional instruments as well as manpower to enhance its R&D capability to deliver more advanced and efficacious dosage forms in oral solids, oral liquid and some APIs. During the year, main activity areas were on expanding the knowledge base about Placentrex constituents. Two new products were introduced in the domestic market and some out-sourced products are almost ready with improved quality versions for commercial exploitation.”
To expand the geographical reach of the company’s products in export market, number of dossiers have been submitted in different countries. Approval of some dossiers has been received during this financial year.
Commenting on the Indian pharma industry, he said that the Indian pharma industry is passing through challenging times. It is witnessing a big change due to the government’s pricing policy and severe price competition.
But inspite of these, Albert David will continue to grow with the current strategies in place and is equipped to meet any future challenges, he added.
EP New Bureau – Kolkata
Comments are closed.